Echinacea purpurea to treat Novel Coronavirus (2019-nCoV)
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
Novel Coronavirus (2019-nCoV) or Human Coronavirus (HCoV) could be a new coronavirus that belongs to Betacoronaviruses type Human Coronaviruses, just like the Middle-East Respiratory Syndrome (MERS) coronavirus and Severe Acute Respiratory Syndrome (SARS) coronavirus. Wuhan, the capital city of Hubei province, China recorded the initial cases of this virus in December 2019. Until 2 May 2020, 10:00 CET, near 23,8287 deaths were reported out of 3.34 million confirmed cases recorded across the world. By the tip of January 2020, China confirmed that the COVID-19 transmitted from human to human. This study aims to check a completely unique medicament called “Echinacea purpurea” against the crystal structure of 2019-nCoV Main Protease. This study presents an ideal model for Echinacea purpurea to be tested in silico against 2019-nCoV Main Protease.